Virtual Prediction of Thymoquinone and β-Glucan Interaction as Estrogen Receptor-Alpha (ER-α receptor) May Reducing on The Breast Cancer Signaling Pathway
DOI:
https://doi.org/10.21776/ub.jsmartech.2019.001.01.1Keywords:
thymoquinone, β-glucan, β-estradiol, ER-α receptor, breast cancerAbstract
Many cases of chemical drug treatment in breast cancer patients result in a negative impact on drug resistance. Therefore the use of natural compounds such as β-glucan on ajwa dates and thymoquinone on black cumin was expected to stop the process of cancer cell proliferation and to consume in long-term safety. This study aimed to predict the effect of thymoquinone and β-glucan in reducing breast cancer cascade with molecular docking. This research was carried out in silico. The ligand and protein preparations were done using Discovery Studio 2016. We used Hex 8.0.0 for docking. Visualization was established using Discovery Studio 2016 as well. The results showed that thymoquinone and β-glucan can undergo conformational changes in ligand binding domain (LBD) of ER-α receptor. The interaction between ER-α receptor with β-estradiol (inhibited by thymoquinone-β-glucan) was suggested to be the best solution in downregulating breast cancer signaling pathway. This interaction showed more stable conformation with the smallest binding energy (-332,84 kcal/mol). The thymoquinone-β-glucan complex could block the His476 and Met438.
References
De Santis, C., M. Jiemin, B. Leah & J. Ahmedin, Breast Cancer Statistics, 2013, Pp. 1-11.
GLOBOCAN, Cancer in Africa, http://globocan.iarc.fr, 2008, Accessed on March, 18th 2019.
Kementrian Kesehatan Republik Indonesia, Hari Kanker Sedunia, 2019, www.depkes.go.id. Accessed on March, 18th 2019.
Yared, Y.G & A.B. Birhane, IJPSR, 2015, 6(8). Pp. 1100-1104.
Motaghed, M., American Journal of Life Sciences, 2015, 3(2), Pp. 7-14.
Khan,. M.A., T. Mousumi., F. Shangyi, & F. Junjiang, Oncotarget Review, 2017, 8 (31). Pp. 51907-51919.
Jafaar Z.M.T., M.L Lacey., M.I Margarita., N.R Brandie., A. Numan & M.K Carolyn, International of Oncology, 2014, 44(1), Pp. 1365-1375.
Ostadrahimi, A., E. Ali., A.J Mohammad., E.Z Jamal., M. Aliakbar & F. Nazila, Adv Pharm Bull. 2014, 4(1), Pp. 471-477.
Chamkasem, A. & T. Waraphan, Asian Pac J Cancer Prev, 2016, 16(6), Pp. 2161-2166.
Hoffman, R., E. J. Benz, L. E. Silberstein, H. E. Heslop, J. I. Weitz, J. Anastasi, M. E. Salama, & S.A. Abutalib, Hematology: Basic Principles and Practice 7th Edition, 2018, Elsevier, Amsterdam.
Wermuth, C. G., D. Aldous, P. Raboisson, & D. Rognan, The Practice of Medicinal Chemistry 4th Edition, 2015, Elsevier, Amsterdam.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons - Attribution 4.0 International (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate permission for non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
